Kanda T, Nakamoto S, Wu S, Yokosuka O. Role of IL28B genotype in older hepatitis C virus-infected patients. World J Immunol 2013; 3(3): 54-61 [DOI: 10.5411/wji.v3.i3.54]
Corresponding Author of This Article
Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 3 Severe adverse events in hepatitis C patients aged ≥ 65 years and treated with standard of care n (%)
Severe adverse events
No. of patient
discontinuities
Occurrence of malignancies (Hepatocellular carcinoma)
5 (13.5)
Severe fatigue
5 (13.5)
Severe pulmonary symptoms (bloody phlegm, cough, or interstitial pneumonitis)
5 (13.5)
Severe anemia
5 (13.5)
Psychiatric disorders
3 (8.1)
Severe skin lesion
3 (8.1)
Neurological disorders
3 (8.1)
Severe thrombocytopenia or neutropenia
3 (8.1)
Severe denutrition
2 (5.4)
Upper gastrointestinal bleeding
1 (2.7)
Severe infection (tuberculosis)
1 (2.7)
Unknown
1 (2.7)
Table 4 Association between IL28B rs8099917 and treatment response in hepatitis C patients aged ≥ 65 years and treated with standard of care
Total
IL28B TT
IL28B TG
1P values
(n = 41)
(n = 31)
(n = 10)
Age (yr)
67.7 ± 2.6
68.0 ± 2.9
67.0 ± 1.3
0.141
Gender (male/female)
28/13
22/9
4/6
0.796
HCV viral load, (high/low)
41/0
31/0
10/0
NA
HCV genotype (G1/G2)
41/0
25/6
8/2
0.678
Treatment-naïve (yes/no)
29/12
24/7
5/5
0.208
ALT (IU/L)
56.5 ± 40.2
54.9 ± 41.2
61.1 ± 38.9
0.677
γ-GTP (IU/L)
36.4 ± 33.3
33.1 ± 33.1
46.6 ± 33.4
0.269
White blood cells (/μL)
4840 ± 1300
4730 ± 1160
5190 ± 1690
0.337
Hemoglobin (g/dL)
13.5 ± 1.3
13.6 ± 1.1
13.3 ± 1.8
0.528
Platelets (x104/μL)
14.9 ± 5.4
14.4 ± 5.1
16.5 ± 6.2
0.289
IL28B rs8099917 (TT/TG)
31/10
31/0
0/10
NA
EVR rates
34.1% (14/41)
45.1% (14/31)
0% (0/10)
0.025
SVR rates
43.9% (18/41)
48.3% (15/31)
30.0% (3/10)
0.514
Citation: Kanda T, Nakamoto S, Wu S, Yokosuka O. Role of IL28B genotype in older hepatitis C virus-infected patients. World J Immunol 2013; 3(3): 54-61